First Look at Combo With Immunotherapy in Untreated mRCC – Medscape
Medscape |
First Look at Combo With Immunotherapy in Untreated mRCC
Medscape ORLANDO, Florida – Use of the immunotherapy atezolizumab (Tecentriq, Roche) in combination with bevacizumab (Avastin, Roche) nearly doubled progression-free survival (PFS) compared with sunitinib (Sutent, Pfizer) as a first-line treatment in patients … |
